By Stephen Nakrosis The Food and Drug Administration said it granted approval of Ixchiq, the first vaccine for chikungunya virus, to Valneva Austria. Valneva.
By Andrea Figueras Valneva reported a narrowed loss for the first half, thanks to sharply reduced costs that offset a decline in revenue due to the effects.
By Cecilia Butini Valneva has received positive safety data in a Phase 3 trial studying a vaccine against the mosquito-borne chikungunya virus. Data showed.
By Maitane Sardon Valneva said Monday that the U.S. Food and Drug Administration has delayed the target date for completing the regulatory review of the.